Neuroone Medical Technologies

Name

Neuroone Medical Technologies

Legal name

NeuroOne Medical Technologies Corporation

Website

https://n1mtc.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Neurological Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Neurological medical devices
• Radiofrequency ablation systems
• Thin film electrodes
• Brain mapping technology
• Neurosurgical instruments

Headquarters

HQ city

Eden Prairie

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: NeuroOne generates revenue through the sale of its FDA-cleared medical devices including the OneRF Ablation System and Evo sEEG electrode line. Product revenue grew from $3.5 million in fiscal year 2024 to $9.1 million in fiscal year 2025, driven by sales of the OneRF Ablation System. Revenue is generated through direct sales and distribution partnerships including the exclusive distribution agreement with Zimmer, Inc.
2. Distribution Agreement Payments: The company receives upfront payments and milestone payments through distribution partnerships. Zimmer, Inc. paid $3.0 million upfront for exclusive distribution rights to the OneRF Ablation System, plus potential milestone payments.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

NeuroOne Medical Technologies develops and commercializes thin film electrode-based medical devices for the diagnosis and treatment of neurological disorders. The company's core product portfolio includes the FDA-cleared OneRF Ablation System for radiofrequency brain ablation, the Evo sEEG Electrode Line for brain mapping and seizure monitoring, and a drug delivery neural probe program in development. These products are sold to hospitals, neurosurgery centers, and pain management specialists through direct sales and an exclusive distribution agreement with Zimmer, Inc.

Product overview

NeuroOne Medical Technologies develops a portfolio of neurological treatment solutions centered on its thin film electrode technology platform. The core product offerings include the FDA-cleared OneRF Ablation System for radiofrequency ablation procedures and the Evo sEEG Electrode Line for brain mapping and seizure monitoring. The company is also developing a drug delivery electrode program using neural probes to potentially overcome blood-brain barrier limitations. The company distributes products through partnerships including an amended distribution agreement with Zimmer, Inc. for exclusive OneRF Ablation System distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• OneRF Ablation System FDA-cleared radiofrequency ablation system for brain ablation procedures and trigeminal nerve ablation. Designed for minimally invasive treatment of neurological conditions including trigeminal neuralgia, sold to hospitals and neurosurgery centers.
• Evo sEEG Electrode Line Stereoelectroencephalography (sEEG) thin film electrodes for brain mapping and seizure monitoring during epilepsy evaluation procedures. Sold to hospitals, neurosurgery centers, and neurology practices in the U.S. market.
• OneRF Trigeminal Nerve Ablation System FDA-approved minimally invasive device for delivering targeted radiofrequency ablation to treat trigeminal neuralgia, approved in August 2025. Limited commercial release launched in Q1 FY2026 for pain management specialists and neurosurgeons.

Quantifiable outcome

• Revenue growth of 160% from FY2024 ($3.5M) to FY2025 ($9.1M)
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Global Medical Technology Company (Undisclosed)minorChannel Partner/ Reseller/ Distributor · 5 August 2024NeuroOne signed a non-binding term sheet with a global medical technology company to distribute its OneRF Ablation System. The partnership was expected to close by the end of Q3 2024, though the company name remains undisclosed pending final agreement.
• Zimmer, Inc.coreChannel Partner/ Reseller/ DistributorNeuroOne entered an amended distribution agreement with Zimmer, Inc. granting exclusive rights to distribute the OneRF Ablation System. Zimmer paid $3.0 million upfront plus potential milestone payments. This represents a significant channel partnership for commercializing the company's primary therapeutic product.
• Strategic Partners for Licensing/PartnershipsminorStrategic or Co-development PartnerNeuroOne is in ongoing diligence discussions with strategic partners for potential licensing or partnerships on its trigeminal nerve and back pain platforms. These discussions are in early stages and specific partners have not been disclosed.

Scale indicators20 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Penumbra: Penumbra develops interventional neurovascular and neurosurgical devices. It is directly comparable in scale and neuro focus, and NeuroOne's recent board appointee is Penumbra's EVP of Strategy, underscoring adjacency in the neurosurgery device category.
• Axonics: Axonics develops sacral neuromodulation devices. It is a comparable small-cap neuromodulation commercial-stage company with similar commercialization, reimbursement, and capital-raise considerations.
• Stereotaxis: Stereotaxis develops robotic systems for electrophysiology and neurovascular procedures. It is comparable as a small-cap, growth-stage neuro-intervention medtech selling capital and disposable products into the same neurosurgery channels.
• Nevro: Nevro is a neuromodulation pure-play focused on spinal cord stimulation. It is directly comparable as a small-cap, growth-stage neuromodulation company navigating similar reimbursement and adoption dynamics.
• Inspire Medical Systems: Inspire Medical markets an implantable neurostimulation device for obstructive sleep apnea. It is a directly comparable neurostim pure-play that scaled from a small base into a meaningful public medtech.

Emerging players

• ElectroCore: ElectroCore develops non-invasive vagus nerve stimulation devices. It is an emerging neurostim peer with comparable small-cap scale, similar neurological indications, and overlapping physician customer segments.

Broad incumbents

• Boston Scientific: Boston Scientific operates a sizable neuromodulation franchise (spinal cord stimulation, VNS, deep brain stimulation). It is a broad incumbent competing for similar hospital neuroscience budgets and physician mindshare.
• Medtronic: Medtronic is the global leader in deep brain stimulation and neuromodulation, and operates broadly in neurosurgery. Its DBS franchise competes for the same neurosurgery hospital budgets and physician relationships targeted by NeuroOne.
• Integra LifeSciences: Integra is a large neurosurgery device company offering electrodes, monitors, and surgical instruments used in similar procedures to NeuroOne's Evo sEEG and OneRF products, making it a broad incumbent peer in the same hospital channels.
• Abbott: Abbott markets deep brain stimulation and other neuromodulation devices. As a broad incumbent, it competes with NeuroOne for neurosurgery centers and presents the kind of large strategic competitor that could enter thin-film electrode space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/N1MTC

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds20 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuroone Medical Technologies